<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d26947238e95">Precision oncology aspires to align cancer patients with therapies that most effectively ...

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d4280225e217">This report explores a therapeutic hypothesis for addressing the potential effects of a ...

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d90562e89">The NIH NCATS Translator program now exposes <b>&gt; 200 million semantically...

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d9292592e148">Drug repurposing provides a cost-effective approach to identifying new therapeutic indic...

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d13493990e380">The development of new drugs is hindered by high failure rates, substantial costs, and ...

<p>This conference will provide a platform to discuss the latest trends, European initiatives and success stories in the use of existing drugs. In addition, round table discussions will address the ch...

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d392105e255">Network-based drug repurposing requires the seamless synthesis of knowledge from both the...

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d814479e258">Complex diseases often lack an actionable understanding of their underlying causal biolog...

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d1367117e186">Large-scale drug sensitivity screens have enabled training drug response prediction mode...

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d26893407e114">Despite advances in modern medicine that led to improvements in cardiovascular outcomes, ...

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d2881e105"> <b>Background:</b> Health Technology Assessment (HTA) is a multi...

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d1880278e181">Migraine prophylaxis remains an area of substantial unmet medical need. Current therapies ...

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d13555163e151">Cri du Chat syndrome (CdCS) is a rare genetic disorder caused by spontaneous deletion o...

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d276929e183">Despite decades of translational research, translational stroke research has yield to no ...

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d816596e219">B cell lymphomas (BCL) are a heterogenous group of hematologic malignancies, with over 70 identified subtypes. Current first line treatment for all subtypes is rituximab and chemotherapy regimen (R-CHOP); of the treated patients, up to 40-60% relapse or have refractory disease, with typically higher mortality rates. Therefore, more efficient treatment, but also improved <i>ex vivo</i> research models are needed to study the treatment response and resistance. To overcome the expensive and time-consuming process of drug discovery and development, we aim to combat the lymphoma heterogeneity with repurposed drugs, especially focusing on cationic amphiphilic drugs (CADs) that damage cancer cell lysosomes. </p><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d816596e224">Lysosomes are central organelles in nutrient sensing and cellular metabolism. Malignant transformation rewires cellular metabolism to boost growth. In turn, cancer cells increase lysosomal production and activity to meet the metabolic needs. Our current results indicate that targeting the reported cancer cell lysosomal ‘weakness’ with repurposed CADs Ebastine and Penfluridol prevents pro-survival cell signaling, and suppresses long-term tumor outgrowth in B lymphoma cell lines, patient blood B cells, and in patient lymph node-derived organoids. </p><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d816596e226">We have developed a novel patient-derived lymphoma organoid model as an <i>ex vivo</i> drug assay platform from patients’ own cancer tissue. With combining the lymphoma organoid model and repurposed drugs, this study provides a simpler and cost-effective, yet translationally relevant clinical solution for personalized medicine and improved treatment of BCL patients. </p>

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d26971189e181">Precision oncology benefits only a subset of patients, with approved drugs targeting le...

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d446414e216">Advanced thyroid cancer patients have limited treatment options and rarely result in a cu...

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d13111663e103">Drug discovery is both a long and expensive process, characterized by low success rates and high…